Natera and Vertex Pharmaceuticals are working together to raise awareness about the genetic causes of kidney disease in the Black community and to reduce the barriers associated with genetic testing. Vertex Pharmaceuticals is sponsoring a no-cost testing program with Natera to provide the Renasight™ genetic test and genetic counseling to eligible* individuals. Through this program more patients will have access to genetic testing which may help to provide answers explaining the increased risk of kidney disease and provide clarity for improved disease management decisions.
American Association of Kidney Patients (AAKP) has partnered with Emory University to provide complimentary genetic testing for individuals at-risk and families affected by Fabry Disease. AAKP and Emory are able to provide this free service and Fabry disease education thanks to contributions from Sanofi-Genzyme, Inc., and Amicus Therapeutics – companies known for their expertise and commitment in the area of rare genetic diseases.
Kyowa Kirin Inc. and Invitae have partnered to offer sponsored, no-charge genetic testing and counseling to patients being evaluated for a possible diagnosis of X-linked hypophosphatemia (XLH) or tumor-induced osteomalacia (TIO), are aged 6 months or older (for XLH) and 2 years or older (for TIO), reside in the United States or Canada, and meet certain other eligibility criteria.
An accurate diagnosis may impact the clinical management of the condition, including customizing care to a patient’s specific needs. The Kyowa Kirin Sponsored Hypophosphatemia Panel (13 genes) is designed to provide optimal diagnostic yield for patients with genetic forms of hypophosphatemia, based on the current scientific understanding. This panel also provides reasonable exclusionary yield for patients who are suspected of having TIO, in whom we would expect normal genetic test results.
The Kyowa Kirin Sponsored Hypophosphatemia Program is intended to improve patient safety and quality of care by shortening the time to an accurate diagnosis, facilitate prompt confirmatory testing, and help patients with XLH or TIO meet payor coverage requirements. Use of or participation in the Kyowa Kirin Sponsored Hypophosphatemia Program does not create any obligation to use, prescribe, or recommend any Kyowa Kirin products or services. No patient or health care provider may seek reimbursement for testing or counseling services provided under the Kyowa Kirin Sponsored Hypophosphatemia Program from any third party, including but not limited to, any government health care programs.
To provide patients with genetic information that can help establish a diagnosis for XLH or TIO, the program guidelines are as follows:
– While Kyowa Kirin provides financial support for this program, tests and services are performed by independent third parties. – Healthcare professionals must confirm that patients meet certain criteria to use the program. – Healthcare professionals or patients using this program are not obligated to recommend, purchase, order, prescribe, promote, administer, use, or support any Kyowa Kirin product. – No patients, healthcare professionals, or payers, including government payers, are billed for this program. – Kyowa Kirin will not receive any individual test result data, personally identifiable information, or physician ordering information. Any data that may be transmitted will be de-identified and aggregated.
This program offers seamless, no-charge genetic testing, primary hyperoxaluria (PH)–specific metabolite testing, and optional genetic counseling to help you identify the genetic cause of your patient’s kidney stones and provide clarity to guide your next steps.
